NCT05570149 EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.
| NCT ID | NCT05570149 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS San Raffaele Roma |
| Condition | Migraine Disorders |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2023-01-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population.
Eligibility Criteria
KEY INCLUSION CRITERIA 1. Age between 18 and 75 years; 2. Males and females; 3. Willingness to sign the informed consent; 4. High frequency episodic migraine, at least 8 days per month of disabling migraine in the past 3 months; 5. Chronic migraine, according to the ICHD-III criteria; KEY EXCLUSION CRITERIA 1. Other headaches different than migraine; 2. Known intolerance to eptinezumab or eccipients; 3. Current treatment with other mAbs; 4. Vascular disease or Raynaud.
Contact & Investigator
Piero Barbanti, MD, PhD
STUDY CHAIR
IRCCS San Raffaele Roma
Frequently Asked Questions
Who can join the NCT05570149 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Migraine Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05570149 currently recruiting?
Yes, NCT05570149 is actively recruiting participants. Contact the research team at piero.barbanti@sanraffaele.it for enrollment information.
Where is the NCT05570149 trial being conducted?
This trial is being conducted at Roma, Italy.
Who is sponsoring the NCT05570149 clinical trial?
NCT05570149 is sponsored by IRCCS San Raffaele Roma. The principal investigator is Piero Barbanti, MD, PhD at IRCCS San Raffaele Roma. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.